Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp's Q2 Revenues Rise 3 Percent

NEW YORK (GenomeWeb) – Laboratory Corporation of America reported today that its second quarter revenues increased around 3 percent year over year as the firm beat Wall Street estimates on the top and bottom line.

The Burlington, NC-based clinical lab giant reported revenues of $1.52 billion for the three months ended June 30, up from $1.47 billion for Q2 2013. Analysts, on average, had estimated revenues of $1.50 billion.

LabCorp said that revenues were driven by a 5 percent increase in test volume year over year, though its revenue per requisition decreased 2 percent due to test and payer mix.

The firm posted net income of $141.3 million, or $1.64 per share, compared to $151.9 million, or $1.62 per share, for Q2 2013. On an adjusted basis, its EPS was $1.84, compared to $1.80 for Q2 2013 and above the consensus Wall Street estimate of $1.77.

"We are pleased with the strong volume growth in the quarter and the sequential stability of revenue per requisition, which has been under pressure due to mix," LabCorp Chairman and CEO David King said in a statement.

LabCorp reported SG&A expenses of $297.9 million for the quarter, an increase of 6 percent over Q2 2013 SG&A spending of $280.9 million.

The firm said that it expects FY 2014 revenue growth approximately 2 percent with adjusted EPS in a range of $6.50 to $6.75 — that's an increase from previous guidance of $6.40 to $6.70.

In Friday morning trade on the New York Stock Exchange, shares of LabCorp were down around 2 percent at $102.88.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.